CBG
Cannabigerol · Mother cannabinoid
Non-intoxicating minor cannabinoid considered a precursor to other cannabinoids, with emerging but limited clinical evidence.
Key caution
Clinical evidence is emerging and limited
Editorial review status — shown for transparency
AI Context
Deterministic summaries of curated archive data. Not medical advice. Not a use guide.
CBG: profile overview
CBG is a cannabinoid with limited evidence quality and a low risk profile. Non-intoxicating minor cannabinoid considered a precursor to other cannabinoids, with emerging but limited clinical evidence. Individual responses vary significantly. This summary is drawn from the curated SubsAtlas archive.
- Risk profile: Low — generally lower concern based on available evidence and known interaction context.
- Evidence quality: Limited — early or narrow research — uncertainty is significant.
- Key caution: Clinical evidence is emerging and limited
- Interaction concerns noted with: Certain medications without professional review.
- Primary compounds: Cannabigerol (CBG).
Clinical evidence is emerging and limited
Limitations
- Based on curated SubsAtlas archive data only.
- Not medical advice. Not legal advice. Not a use guide.
- Individual responses vary. Source review is ongoing.
- Do not rely on this for personal decisions.
AI Context summarizes curated SubsAtlas archive data only. Not medical advice. Not legal advice. Not a use guide. No external AI calls are made.
Quick Facts
Concise educational context for orientation. Effects and risks vary.
Category
cannabinoid
Main compounds
Cannabigerol (CBG)
Reported profile
Mild alertness, Focus reports, Reduced tension reports
Onset range
Varies by context and product type
Duration range
General educational range only
Main caution
Clinical evidence is emerging and limited
Body & Mind Map
Visual summary of reported effect patterns. Effects vary.
Community Signal
Community Signal is based on anonymous structured reports. It does not represent a recommendation.
Common warning
Community Signal requires moderated structured reports.
Risk awareness
Clear cautions, uncertainty and interaction concerns. This is not medical advice.
Main risks
- Clinical evidence is emerging and limited
- Product quality and label accuracy vary
- Medication interaction concerns through shared metabolic pathways
Avoid if…
- You have relevant medical concerns without professional guidance
- You are in an unsafe setting
- You need to drive or operate machinery
Do not combine with…
- Certain medications without professional review
Medical caution
- Review medication interactions with a qualified professional
- Seek professional help for medical concerns
Unknowns
- Product quality may vary
- Individual response varies
- Evidence may be incomplete
Interaction Warnings
Interaction concerns are shown for risk awareness only. SubsAtlas does not describe any combination as safe.
- May affect the metabolism of some medications through shared liver enzyme pathways.
General onset
Varies by context and product type
Peak
Varies by substance, product and person
Duration
General educational range only
After effects
May vary; monitor uncertainty and risk context
Timeline ranges are general educational context, not instructions.
Sources
Evidence quality, source type and review context are separated from community patterns.
Sources need editorial review
Sources listed here have not yet completed editorial review. They are shown for transparency, not as verified citations. What source review means
Curated CBG cannabinoid education profile
editorial source · Reviewed 2026-05-16
Source status: needs-review · How source review works
Legal context
Legal status varies by country, state and local regulation. This is educational context only — not legal advice.
Legal status varies by jurisdiction; often follows cannabis regulatory frameworks.
Legal status varies by country, state and local regulation. SubsAtlas provides educational context only and does not provide legal advice, sourcing or buying guidance.
Legal context requires ongoing review as laws change. How legal context works
Similar Entries
Related educational profiles for comparison and context.
CBD
Non-intoxicating cannabinoid discussed for calm and sleep support. Medication interaction concerns and significant product quality variation are key considerations.
Main caution
Significant drug interaction potential — CBD affects liver enzymes that metabolise many medications
Legal: Legal context varies
CBN
Minor cannabinoid associated with sedation-related reports and limited clinical evidence, primarily found in aged cannabis.
Main caution
Clinical evidence for specific effects is limited
Legal: Legal context varies
THC
Primary intoxicating cannabinoid in cannabis. Clear impairment risks, dependence potential and adverse mental health outcomes at high-dose or regular use.
Main caution
Impaired memory, attention and psychomotor function — do not drive or operate machinery
Legal: Legal context varies
Cannabis
Plant profile covering cannabinoids, terpenes, reported effects, impairment, dependence, legal variation and risk context across a wide range of products.
Main caution
Impaired coordination, memory and judgment — do not drive or operate machinery
Legal: Legal context varies
Shareable cards
Visual educational summaries featuring this profile.
Contribute a structured report
Help future Community Signal summaries by submitting a structured educational report. Reports are stored locally in this MVP and are not published publicly.
Educational information only. Not medical advice. No personalized dosing, sourcing, preparation or optimization guidance.